Evidence map›Paper›PMID 41883711›Full record

ArticleBMEmat2024

Is deep brain imaging on the brink of transformation with a bioluminescence molecule?

Shumao Xu, Farid Manshaii, Jun Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMEmat, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shumao XuDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, USA.ORCID 0000-0003-2062-0226
Farid ManshaiiDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, USA.ORCID 0009-0007-4580-9259
Jun ChenDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, USA.ORCID 0000-0002-3439-0495

Funding

The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1M
A soft magnetoelastic microneedle patch for rapid skin cancer screeningR01CA287326 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Jun Chen · 2024 to 2026
$1.1M
American Heart Association-American Stroke Association 23IPA1054908American Heart Association-American Stroke Association 23SCEFIA1157587American Heart Association-American Stroke Association 23TPA1141360NCATS NIH HHS KL2 TR001882NCI NIH HHS R01 CA287326
6 · The paper itself

Abstract

Cephalofurimazine (CFz), when paired with Antares luciferase, shows superior blood-brain barrier permeability and enhanced imaging depth and clarity for deep brain imaging. This bioluminescence provides a less invasive method for real-time monitoring of deep brain activity, with the potential to advance targeted therapies and deepen our understanding of brain functions. Further molecular engineering and localized delivery can reduce the potential toxicity of CFz and enhance its efficacy for clinical deep brain imaging.

Indexed as

bioluminescence moleculeblood-brain barrierbrain imaging

Identifiers

PMID41883711
PMCPMC13012793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.